Fibromyalgia: The diagnosis and pharmacologic treatment

Dan Buskila

doi:10.1016/j.eujps.2009.07.007

Fibromyalgia: The diagnosis and pharmacologic treatment

Dan Buskila

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Fibromyalgia (FM) is a chronic condition characterized by widespread pain and diffuse tenderness along with a constellation of ancillary symptoms. The 1990 ACR criteria for classification of FM are important in enhancing much the research of FM. FM is part of a spectrum of functional somatic syndromes. FM is not a homogenous condition and several subtypes of FM had been determined. The best strategy for management of FM is to use a multidisciplinary approach to treatment using both pharmacological and non-pharmacological interventions. Tramadol, tricyclic drugs, mixed reuptake inhibitors and anticonvulsants show efficacy in this condition. Recently, three drugs: pregabalin, duloxetine and milnacipran have been approved by the FDA for treatment of FM.

Original language	English
Pages (from-to)	111-115
Number of pages	5
Journal	European Journal of Pain Supplements
Volume	3
Issue number	2
DOIs	https://doi.org/10.1016/j.eujps.2009.07.007
State	Published - 1 Nov 2009

Keywords

Alpha 2 delta ligands
Chronic widespread pain
Fibromyalgia
Functional somatic syndromes
Pharmacologic treatment
Reuptake inhibitors

ASJC Scopus subject areas

Anesthesiology and Pain Medicine

Access to Document

10.1016/j.eujps.2009.07.007

Cite this

@article{373d13b176d346e69d86439d8d76eb51,

title = "Fibromyalgia: The diagnosis and pharmacologic treatment",

abstract = "Fibromyalgia (FM) is a chronic condition characterized by widespread pain and diffuse tenderness along with a constellation of ancillary symptoms. The 1990 ACR criteria for classification of FM are important in enhancing much the research of FM. FM is part of a spectrum of functional somatic syndromes. FM is not a homogenous condition and several subtypes of FM had been determined. The best strategy for management of FM is to use a multidisciplinary approach to treatment using both pharmacological and non-pharmacological interventions. Tramadol, tricyclic drugs, mixed reuptake inhibitors and anticonvulsants show efficacy in this condition. Recently, three drugs: pregabalin, duloxetine and milnacipran have been approved by the FDA for treatment of FM.",

keywords = "Alpha 2 delta ligands, Chronic widespread pain, Fibromyalgia, Functional somatic syndromes, Pharmacologic treatment, Reuptake inhibitors",

author = "Dan Buskila",

year = "2009",

month = nov,

day = "1",

doi = "10.1016/j.eujps.2009.07.007",

language = "English",

volume = "3",

pages = "111--115",

journal = "European Journal of Pain Supplements",

issn = "1754-3207",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Fibromyalgia

T2 - The diagnosis and pharmacologic treatment

AU - Buskila, Dan

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Fibromyalgia (FM) is a chronic condition characterized by widespread pain and diffuse tenderness along with a constellation of ancillary symptoms. The 1990 ACR criteria for classification of FM are important in enhancing much the research of FM. FM is part of a spectrum of functional somatic syndromes. FM is not a homogenous condition and several subtypes of FM had been determined. The best strategy for management of FM is to use a multidisciplinary approach to treatment using both pharmacological and non-pharmacological interventions. Tramadol, tricyclic drugs, mixed reuptake inhibitors and anticonvulsants show efficacy in this condition. Recently, three drugs: pregabalin, duloxetine and milnacipran have been approved by the FDA for treatment of FM.

AB - Fibromyalgia (FM) is a chronic condition characterized by widespread pain and diffuse tenderness along with a constellation of ancillary symptoms. The 1990 ACR criteria for classification of FM are important in enhancing much the research of FM. FM is part of a spectrum of functional somatic syndromes. FM is not a homogenous condition and several subtypes of FM had been determined. The best strategy for management of FM is to use a multidisciplinary approach to treatment using both pharmacological and non-pharmacological interventions. Tramadol, tricyclic drugs, mixed reuptake inhibitors and anticonvulsants show efficacy in this condition. Recently, three drugs: pregabalin, duloxetine and milnacipran have been approved by the FDA for treatment of FM.

KW - Alpha 2 delta ligands

KW - Chronic widespread pain

KW - Fibromyalgia

KW - Functional somatic syndromes

KW - Pharmacologic treatment

KW - Reuptake inhibitors

UR - http://www.scopus.com/inward/record.url?scp=70350574139&partnerID=8YFLogxK

U2 - 10.1016/j.eujps.2009.07.007

DO - 10.1016/j.eujps.2009.07.007

M3 - Article

AN - SCOPUS:70350574139

SN - 1754-3207

VL - 3

SP - 111

EP - 115

JO - European Journal of Pain Supplements

JF - European Journal of Pain Supplements

IS - 2

ER -

Fibromyalgia: The diagnosis and pharmacologic treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this